Canadian Journal of Public Health

, Volume 108, Issue 1, pp e95–e97 | Cite as

The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the country

  • Howard H. FeldmanEmail author
  • Carole A. Estabrooks


In the next 15 years, Canada is predicted to face a doubling in its population affected by dementia. By 2038, an estimated 1.1 million Canadians will be experiencing dementia, with unprecedented impact on social, economic and health landscapes. In September 2015, the Canadian Academy of Health Sciences convened a Forum, with the specific thematic goals of reviewing progress towards effective dementia treatment and prevention, improved systems of care, advanced living and built environments, and impactful technology developments. The orientation of the Forum was to focus on potential solutions and advances in these areas. These areas are integral to the goal of a national end-to-end program, where all affected Canadians can be optimally supported in their communities and receive quality of care - regardless of where they live or who they are.


D’ici 15 ans, la population du Canada atteinte de démence devrait doubler. D’ici 2038, environ 1,1 million de Canadiens seront atteints de démence, ce qui aura un impact sans précédent sur le paysage social, économique et sanitaire. En septembre 2015, l’Académie canadienne des sciences de la santé a convoqué un forum dont les objectifs étaient d’examiner les progrès réalisés en vue d’améliorer l’efficacité du traitement et de la prévention de la démence, les systèmes de soins, les milieux de vie et les cadres bâtis, ainsi que l’impact des développements technologiques. Le forum a abordé les possibilités de prévenir la démence, d’offrir des systèmes de soins améliorés, de refaçonner nos milieux de vie et nos cadres bâtis, et de miser sur des solutions technologiques. Ces thèmes s’inscrivent dans l’objectif d’avoir un programme coordonné à l’échelle nationale capable de soutenir de façon optimale, dans leurs communautés, tous les Canadiens touchés par la démence et de leur offrir des soins de qualité, peu importe où ils vivent ou qui ils sont.

Key Words

Dementia prevention national strategy services 

Mots Clés

démence prévention stratégie nationale services 


  1. 1.
    Alzheimer Society of Canada. Dementia Numbers in Canada, 2017. Available at: (Accessed February 6, 2017).Google Scholar
  2. 2.
    Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med 2013;369(24):2275–77. PMID: 24283198. doi: 10.1056/NEJMp1311405.CrossRefGoogle Scholar
  3. 3.
    Alzheimer Society of Canada. Rising Tide: The Impact of Dementia on Canadian Society, 2010. Available at: (Accessed February 6, 2017).Google Scholar
  4. 4.
    Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349(9068):1793–96. PMID: 9269213. doi: 10.1016/S0140-6736(97)01007-6.CrossRefGoogle Scholar
  5. 5.
    Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015: The Global Impact of Dementia–An Analysis of Prevalence, Incidence, Cost and Trends, 2015. Available at: (Accessed February 6, 2017).Google Scholar
  6. 6.
    Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366(9503):2112–17. PMID: 16360788. doi: 10.1016/S0140-6736(05)67889-0.CrossRefGoogle Scholar
  7. 7.
    Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med 2014;275(3):229–50. PMID: 24605807. doi: 10.1111/joim.12178.CrossRefGoogle Scholar
  8. 8.
    Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):311–21. PMID: 24450890. doi: 10.1056/NEJMoa1312889.CrossRefGoogle Scholar
  9. 9.
    Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):322–33. PMID: 24450891. doi: 10.1056/NEJMoal304839.CrossRefGoogle Scholar
  10. 10.
    Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. LancetNeurol 2014;13(8):788–94. PMID: 25030513. doi: 10.1016/S1474-4422(14)70136-X.Google Scholar
  11. 11.
    Sindi S, Mangialasche F, Kivipelto M. Advances in the prevention of Alzheimer’s disease. F1000Prime Rep 2015;7:50. PMID: 26097723. doi: 10.12703/P7-50.CrossRefGoogle Scholar
  12. 12.
    Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet 2015;385(9984):2255–63. PMID: 25771249. doi: 10.1016/S0140-6736(15)60461-5.CrossRefGoogle Scholar
  13. 13.
    Bergman H. Meeting the Challenge of Alzheimer’s Disease and Related Disorders: A Vision Focused on the Individual, Humanism, and Excellence, 2009. Available at: (Accessed February 6, 2017).Google Scholar
  14. 14.
    Morgan DG, Crossley M, Kirk A, D’Arcy C, Stewart N, Biem J, et al. Improving access to dementia care: Development and evaluation of a rural and remote memory clinic. Aging Ment Health 2009;13(1):17–30. PMID: 19197686. doi: 10.1080/13607860802154432.CrossRefGoogle Scholar
  15. 15.
    Alzheimer Society of Canada. Dementia Friends Canada, 2016. Available at: (Accessed February 6, 2017).Google Scholar
  16. 16.
    Alzheimer Society of British Columbia. Dementia-Friendly Communities, 2016. Available at: (Accessed February 6, 2017).Google Scholar
  17. 17.
    Chalmers J. Dementia Friendly City Initiative Halifax, 2014. Available at: 140317.pdf (Accessed February 6, 2017).Google Scholar

Copyright information

© The Canadian Public Health Association 2017

Authors and Affiliations

  1. 1.Department of Neurosciences, Alzheimer’s Disease Cooperative StudyUniversity of CaliforniaSan DiegoUSA
  2. 2.Division of Neurology, Department of MedicineUniversity of British ColumbiaVancouverCanada
  3. 3.Faculty of NursingUniversity of AlbertaEdmontonCanada

Personalised recommendations